by Kimberly Waller | Sep 18, 2026
The US Food and Drug Administration (FDA) has approved Bexlutry (lutetium Lu 177 dotatate) injection for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a generic version of Novartis’...
by Kimberly Waller | Aug 22, 2026
The US Food and Drug Administration (FDA) has approved Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is a disorder in which...
by Kimberly Waller | Aug 12, 2026
Guy Young, MD, Director of the Hemostasis and Thrombosis Program at Children’s Hospital Los Angeles, discusses an ATLAS-OLE subgroup analysis of fitusiran in patients with hemophilia. Hemophilia is a rare bleeding disorder that slows the blood clotting...
by Kimberly Waller | Aug 11, 2026
Caterina Garone, PhD, MD, Associate Professor at the University of Bologna, discusses safety and efficacy data on Kygevvi (doxecitine and doxribtimine) in patients with thymidine kinase 2 deficiency (TK2d). TK2d is a rare genetic disease characterized by...
by Kimberly Waller | Aug 4, 2026
Doug Kerr, MD, PhD, MBA, Chief Medical Officer of Dyne Therapeutics, discusses the initiation of the phase 3 FORZETTO trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51...